Mass spectrometry of antibody conjugates

Details Mass spectrometry of antibody conjugates Mass spectrometry of antibody conjugates

2005-04-06

2010-02-16

Saunders, David A (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Separation or purification

C424S009200, C424S178100, C424S181100, C424S183100, C436S173000, C436S825000, C530S391700, C530S391900

Reexamination Certificate

active

07662936

ABSTRACT:
Methods to detect, screen, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates of Formula I, antibodies, and fragments and metabolites thereof, by affinity separation, chromatography, and mass spectrometry are disclosed.in-line-formulae description="In-line Formulae" end="lead"?Ab-(L-D)p  Iin-line-formulae description="In-line Formulae" end="tail"?whereinAb is an antibody;D is a drug moiety;L is a linker covalently attached to Ab, and covalently attached to D; andp is 1, 2, 3, 4, 5, 6, 7, or 8.

REFERENCES:
patent: 6020208 (2000-02-01), Hutchens et al.
patent: 7329353 (2008-02-01), Dillon et al.
patent: 2002/0197694 (2002-12-01), Shao
patent: 2003/0027216 (2003-02-01), Kiernan et al.
patent: WO 03/046571 (2003-06-01), None
patent: WO 03/046572 (2003-06-01), None
Abdel-Hamid et al., “Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics”J. of Chrom. B 753:401-408 (2001).
Alley, S.C. et al., “Controlling the location of drug attachment in antibody-drug conjugates, Abstract No. 627, American Association for Cancer Research, 2004 Annual Meeting, Mar. 27-31, 2004 Proceedings of the AACR” 45:52 (2004).
Beaudry, F. et al., “In Vivo pharmacokinetic screening in cassette dosing experiments: the use of on-line ProspektRliquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry technology in drug discovery”Rapid Commun. Mass Spectrom. 12:1216-1222 (1998).
Bier, Mark E., “Analysis of proteins by mass spectrometry”Modern Protein Chemistry, Howard and Brown, CRC Press, Chapter 4, pp. 71-88 (2002).
DiJoseph et al., “Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies”Blood103:1807-1814 (2004).
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy”Nature Biotechnology21:778-784 (2003).
Francisco et al., “cAC10-vcMMAE, an anti-CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity”Blood102:1458-1465 (2003).
Hamblett, K. J. et al., “Effect of drug loading on the pharmacology, pharmacokinetics and toxicity of an anti-CD30 antibody-drug conjugate, Abstract No. 624, American Association for Cancer Research; 2004 Annual Meeting, Mar. 27-31, 2004. Proceedings of the AACR” 45 144 (2004).
Hamblett, K. J. et al., “Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate”Clin. Cancer Res. 10:7063-7070 (2004).
Kadkhodayan, M. and Mann, E., “New strategies in characterization and quantitation of antibody-targeted drug conjugates in plasma using LC/LC/MS, 51st Conference on Mass Spectrometry and Allied Topics, American Society for Mass Spectrometry, Montreal, Quebec, Jun. 8-12, 2003” (2003).
Kirchner et al., “Clinical pharmacokinetics of everolimus”Clin. Pharmacokinetics43(2) :83-95 (2004).
Marques et al., “Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics”J. of Chrom. 762:87-95 (2001).
Martin et al., “Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial”Cancer Chemother. Pharmacol. 40:189-201 (1997).
Murray, S. et al., “Identification of human serum interferants in the recombinant P-selectin glycoprotein ligand-1 clinical ELISA using MALDI MS and RP-HPLC”J. Imm. Methods255:41-56 (2001).
Royer et al., “Paclitaxel metabolites in human plasma and urine: identification of 6α-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry”Rapid Comm. in Mass Spec. 9:495-502 (1995).
Sanderson, R. J. et al., “In Vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate”Clin. Cancer Res. 11:843-852 (2005).
Senter, P. et al., “Immunoconjugates comprised of drugs with impaired cellular permeability: a new approach to targeted therapy, Abstract No. 623, presented on Mar. 28, 2004, Proceedings of the American Association for Cancer Research” 45: 144 (2004).
Simpson, H. et al., “High throughput liquid chromatography/mass spectrometry bioanalysis using 96-well disk solid phase extraction plate for the sample preparation”Rapid Commun. Mass Spectrom. 12:75-82 (1998).
Souppart et al., “Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma”J. of Chrom. B 774:195-203 (2002).
Wong et al., “Liquid chromatography-mass spectrometry assay of a thiadiazole derivative in mice: application to pharmacokinetic studies”J. of Chrom. 765:55-62 (2001).
Yao et al., “Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry”J. Chrom. B 752:9-16 (2001).
Yao et al., “Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring”J. of Chrom. B 718:77-85 (1998).
Kruppa et al., “Multiple ion isolation applications in FY-ICR MS: exact-mass MSn internal calibration and purification/interrogation of protein-drug complexes”Anal Chem. 74(15):3877-3886 (Aug. 1, 2002).
Mao et al., “EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer”Cancer Research64:781-788 (2004).
Siegel et al., “Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry”Anal Chem. 69(14):2716-2726 (Jul. 15, 1997).
Siegel et al., “Determination of loading values and distributions for drugs conjugated to proteins and antibodies by MALDI-MS and ESI-MS”Methods Mol Biol. 61:211-226 (1996).
Xie et al, “Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice”J Pharmacol Exp Ther. 308(3) :1073-1082 (Mar. 2004).
Kadkhodayan et al., “A novel approach to characterization of Trastuzumab-DM1 conjugates using LC-MS for confirmation of statistically calculated distributions, 51st Conference on Mass Spectrometry and Allied Topics, American Society for Mass Spectrometry, Montreal, Quebec, Jun. 8-12, 2003” (2003).
Kadkhodayan, M. and Mann, E., “Rapid antibody characterization and Quantitation using automated chip-based nanoelectrospray/MS, 52nd Conference on Mass Spectrometry and Allied Topics, American Society for Mass Spectrometry, Nashville, TN, May 23-27, 2004” (2004).
Mann and Kadkhodayan, “Antibody isolation and Quantitation using LC/MS and a novel 96-well immunoaffinity membrane”52nd Conference on Mass Spectrometry and Allied Topics, American Society for Mass Spectrometry(Nashville, TN, May 23-27, 2004).

Affiliated with

Also associated with

Rating

Mass spectrometry of antibody conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mass spectrometry of antibody conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mass spectrometry of antibody conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4198178